Download PDF

1. Company Snapshot

1.a. Company Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases.


Fulcrum Therapeutics, Inc.has research and discovery collaboration agreement with Acceleron Pharma Inc.to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc.


to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies.Fulcrum Therapeutics, Inc.was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Show Full description

1.b. Last Insights on FULC

Fulcrum Therapeutics' recent performance was negatively impacted by the lack of significant clinical data updates. The company's announcement that it is on track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025, while positive, did not materialize during the recent quarter. Additionally, the company's recent inducement grants to new employees, while a positive sign of growth, may not have had a significant impact on the company's short-term performance.

1.c. Company Highlights

2. Fulcrum Therapeutics: Pociridir Shows Promising Results in Sickle Cell Disease Treatment

The company's EPS came in at -$0.31, in line with estimates. The stock's financial performance is expected to witness a significant revenue growth of 115722.9% next year. With a current 'P/E Ratio' of -7.09 and 'P/S Ratio' of 0.0, it's clear that the market is pricing in high growth expectations for Fulcrum Therapeutics. The 'EV/EBITDA' ratio stands at -3.44, indicating that the company's enterprise value is not justified by its current earnings.

Publication Date: Mar -02

📋 Highlights
  • Robust HbF Induction: 20-mg cohort achieved a 12.2% mean absolute increase in HbF (7.1% to 19.3%) at week 12, with 50%+ reaching ≥20% HbF.
  • Significant Hemoglobin Increase: Total hemoglobin rose >1 gram/dL after 12 weeks, reflecting reduced hemolysis and improved red blood cell function.
  • VOC Reduction in Severe SCD: 7/12 severe patients reported no vaso-occlusive crises during treatment, indicating potential for crisis prevention.
  • Expert Validation of Efficacy: Dr. Steinberg highlighted pociridir’s superiority over hydroxyurea, noting higher HbF levels and uniform F cell distribution.
  • Regulatory and Market Strategy: Planned FDA discussions in 2026, potential registration trial by late 2026, and 2-year lead over competitors (WIZ degraders) due to robust dose-response data.

Treatment Efficacy and Clinical Relevance

The 20-milligram cohort of the Phase 1b PIONEER trial of pociridir showed a 12.2 mean absolute increase in HbF from 7.1% to 19.3% at week 12, with more than half of the patients achieving HbF levels at or above 20%. As Dr. Martin Steinberg noted, "the results suggest that the drug will be efficacious in decreasing acute vaso-occlusive events and hemolytic anemia in sickle cell disease." The progression towards pancellularity alongside reductions in key markers of hemolysis resulted in a greater than 1 gram per deciliter increase in total hemoglobin after 12 weeks of treatment.

Future Plans and Regulatory Interactions

Fulcrum Therapeutics plans to initiate a potential registration-enabling trial in the second half of 2026, pending FDA feedback. The company will also engage with the European Medicines Agency in mid-2026 to obtain protocol assistance and feedback on the design of the next trial. With a 'P/B Ratio' of 1.52, the stock appears to be reasonably valued relative to its book value.

Safety and Tolerability

Pociridir continues to be generally well tolerated at the 20-milligram dose, with no treatment-related serious adverse events. The company's focus on developing an oral agent that can induce levels of fetal hemoglobin like pociridir has the potential to make a significant difference in the lives of patients with sickle cell disease.

Market Potential and Competitive Advantage

Fulcrum Therapeutics believes it has a 2-year head start over the next competitor, the WIZ degraders. The company's goal is to maintain this lead before other players enter the market. With a significant unmet need in sickle cell disease, the potential for pociridir to become a leading treatment option is substantial.

3. NewsRoom

Card image cap

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Mar -03

Source: globenewswire.com

Card image cap

Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion

Feb -26

Source: seekingalpha.com

Card image cap

Fulcrum Therapeutics, Inc. (FULC) Q4 2025 Earnings Call Transcript

Feb -24

Source: seekingalpha.com

Card image cap

What's Going On With Fulcrum Therapeutics Stock Tuesday?

Feb -24

Source: feeds.benzinga.com

Card image cap

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025

Feb -24

Source: globenewswire.com

Card image cap

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Feb -24

Source: globenewswire.com

Card image cap

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Feb -17

Source: globenewswire.com

Card image cap

Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?

Feb -12

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Biopharmaceutical

Expected Growth: 10.43%

Fulcrum Therapeutics' 10.43% growth in biopharmaceuticals is driven by increasing demand for rare genetic disorder treatments, strategic partnerships, and a strong pipeline of novel therapies. The company's focus on gene regulation and epigenetics is also contributing to its growth, as well as its ability to leverage AI and machine learning in drug discovery.

7. Detailed Products

Fulcrum's FTX-6058

FTX-6058 is a small molecule designed to increase the expression of FUS, a protein that is deficient in individuals with FSHD.

Fulcrum's Losmapimod

Losmapimod is a p38α/β inhibitor that has been shown to reduce inflammation and improve muscle function in patients with FSHD.

Fulcrum's FTX-020

FTX-020 is a small molecule designed to increase the expression of a key protein involved in the regulation of muscle function.

Fulcrum's Gene Therapy Programs

Fulcrum's gene therapy programs are designed to treat genetic disorders by delivering a healthy copy of a gene to cells.

8. Fulcrum Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Fulcrum Therapeutics, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.

Bargaining Power Of Customers

Fulcrum Therapeutics, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Fulcrum Therapeutics, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, the suppliers also have some leverage due to the specialized nature of their products.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. These barriers make it difficult for new entrants to enter the market.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Fulcrum Therapeutics, Inc. faces intense competition from companies with similar products and technologies.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 4.40%
Debt Cost 3.95%
Equity Weight 95.60%
Equity Cost 15.68%
WACC 15.16%
Leverage 4.60%

11. Quality Control: Fulcrum Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Rigel Pharma

A-Score: 5.7/10

Value: 5.9

Growth: 8.0

Quality: 9.3

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Fulcrum Therapeutics

A-Score: 4.9/10

Value: 6.4

Growth: 8.0

Quality: 4.6

Yield: 0.0

Momentum: 9.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Assembly Biosciences

A-Score: 4.5/10

Value: 6.0

Growth: 3.8

Quality: 4.6

Yield: 0.0

Momentum: 10.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
EyePoint Pharmaceuticals

A-Score: 4.0/10

Value: 6.2

Growth: 2.2

Quality: 4.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Lipocine

A-Score: 3.8/10

Value: 7.7

Growth: 6.8

Quality: 2.7

Yield: 0.0

Momentum: 3.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Clearside Biomedical

A-Score: 3.3/10

Value: 9.4

Growth: 3.6

Quality: 6.1

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

7.87$

Current Price

7.87$

Potential

-0.00%

Expected Cash-Flows